Kang found that the combination of the EGFR/HER2 inhibitors gefitinib and lapatinib with the IGF-1R inhibitor Lincitinib overcomes monotherapy resistance and enhances the antitumor efficacy of ESCC (38). Here, ERBB2 is linked to esophageal squamous cell carcinoma.